Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
United States
MD Anderson Cancer Center, Houston, Texas Belgium
Universitair Ziekenhuis Antwerpen (UZA), Edegem, Antwerp Institut Jules Bordet, Anderlecht, Brussels Capital Czechia
Masarykův Onkologický Ústav, Brno Fakultni Nemocnice Olomouc (FNOL) - Onkologicka Klinika, Olomouc France
Institut Gustave Roussy, Paris Spain
Hospital Universitari Vall d'Hebron - Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona